Praxis Precision Medicines, Inc. (PRAX) Stock Price & Analysis

Praxis Precision Medicines, Inc. (PRAX) fell 0.94% to USD 351.81 as of September 8, 2026 at 05:43 UTC, according to Nexqual real-time market data.

PRAX last closed at USD 351.81; the session ranged USD 349.82–357.49 on volume of 175,356 shares. Market capitalization is —, with a 52-week range of USD 37.19–392.7 (NMS). Source: Nexqual, September 8, 2026 at 05:43 UTC.

Key Statistics (as of September 8, 2026 at 05:43 UTC)

Technical Analysis (PRAX)

Nexqual's technical model rates PRAX "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:43 UTC.

From Praxis Precision Medicines, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• We submitted a New Drug Application, or NDA, for ulixacaltamide for the treatment of ET to the FDA, and have commenced commercial preparations and pre-launch activities.
• We may also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of neuroscience that may be important for the development of our business.
• Solidus™ is enabled by our proprietary, computational workflow to discover ASOs with desired drug-like properties to optimize for up/down-regulation, avoidance of toxic motifs and optimization of binding affinity and specificity.
• INTELLECTUAL PROPERTY We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties.

Partnerships

• LICENSE AGREEMENTS License Agreement with RogCon In September 2019, we and RogCon, Inc., or RogCon, entered into a Cooperation and License Agreement, or the RogCon Agreement, to collaborate to develop ASOs for the treatment of epilepsy caused by mutations of the SCN2A gene.
• RogCon had an existing collaboration arrangement with Ionis Pharmaceuticals, Inc., or Ionis, and as a result, we and Ionis negotiated a Research Collaboration, Option and License Agreement, or the Ionis Agreement, (described below) in order to complete the license agreement with RogCon.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:43 UTC. This page is informational and not investment advice.